Anti-angiogenesis and anticancer effects of a plasmid expressing both ENDO-VEGI 151 and small interfering RNA against survivin

International Journal of Molecular Medicine

Volumn 29, Issue 3, 2012, Pages 485-490

  Li, Zhe ^a   Yang, Shengsheng ^b   Chang, Tao ^a   Cao, Xiao ^a   Shi, Linxiang ^a   Fang, Guoen ^b  

^a TONGJI UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Anti angiogenesis; Breast cancer; Gene therapy; Survivin

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; SMALL INTERFERING RNA; SURVIVIN; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

5' UNTRANSLATED REGION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME METABOLISM; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSTATINS; GENE EXPRESSION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; PLASMIDS; RNA, SMALL INTERFERING; TRANSFECTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

EID: 84862935516     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.842     Document Type: Article

References (26)

1. Faye C, Moreau C, Chautard E, et al: Molecular interplay between endostatin, integrins, and heparan sulfate. J Biol Chem 284: 22029-22040, 2009.
2. Reilly JF, Bair L and Kumari V: Heparan sulfate modifies the effects of basic fibroblast growth factor on glial reactivity. Brain Res 759: 277-284, 1997. (Pubitemid 27286706)
3. Zhang N, Sanders AJ, Ye L and Jiang WG: Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med 24: 3-8, 2009.
4. 151 chimeric gene therapy on gastric carcinoma neovascularization. Chin J Exp Surg 22: 1186-1189, 2005.
5. 151 fusion gene therapy on gastric carcinoma in nude mice mediated by adenovirus vector. Chin Med Exp Surg 22: 230-234, 2005.
6. Ryan BM, O'Donovan N and Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-562, 2009.
7. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
8. Butler JM, Kobayashi H and Rafii S: Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10: 138-146, 2010.
9. Weigand M, Hantel P, Kreienberg R and Waltenberger J: Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis 8: 197-204, 2005. (Pubitemid 41759144)
10. Leighl NB, Paz-Ares L, Douillard JY, et al: Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada - Clinical Trials Group Study BR.18. J Clin Oncol 23: 2831-2839, 2005. (Pubitemid 46179474)
11. O'Connor DS, Schechner JS, Adida C, et al: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156: 393-398, 2000. (Pubitemid 30643793)
12. Zhai Y, Ni J, Jiang GW, et al: VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189, 1999. (Pubitemid 29038287)
13. Kerbel RS: Tumor angiogenesis. N Engl J Med 358: 2039-2049, 2008.
14. Quesada AR, Medina MA and Alba E: Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Bioessays 29: 1159-1168, 2007.
15. Fischer C, Jonckx B, Mazzone M, et al: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131: 463-475, 2007. (Pubitemid 350007692)
16. Gasparini G, Longo R, Toi M and Ferrara N: Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2: 562-577, 2005. (Pubitemid 41721816)
17. Shen WG, Zhu J, Zhang Y and Su Q: Synergistic antitumor effects of in vivo production of human endostatin and tissue inhibitor of metalloproteinase-1 in mice after subcutaneous implantation of primary fibroblasts transfected by adenovirus-mediated gene delivery. Chin Med J (Engl) 123: 922-928, 2010.
18. Chen P, Yin H, Wang Y, Mi J, He W and Xie L: Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization. Mol Vis 16: 310-319, 2010.
19. Scappaticci FA, Contreras A, Smith R, et al: Statin-AE: a novel angiostatin-endostatin fusion protein with enhanced antiangiogenic and antitumor activity. Angiogenesis 4: 263-268, 2001. (Pubitemid 34832371)
20. Tysome JR, Briat A, Alusi G, et al: Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancer. Gene Ther 16: 1223-1233, 2009.
21. Li Z, Pan X, Pan W, et al: Packaging and identification of recombinant adenovirus carrying endostatin-soluble vascular endothelial growth inhibitor gene. World Chin J Digestol 11: 741-744, 2003. (Pubitemid 36781905)
22. Pan X, Li Z, Zhang M, Wang Y, Pan W and QI ZT: Therapeutic effect of endostatin-vascular endothelial growth inhibitor recombinant adenoviruses on gastric carcinoma in nude mice. World Chin J Digestol 11: 1282-1285, 2003.
23. Delaney CE, Weagant BT and Addison CL: The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. Exp Cell Res 312: 2476-2489, 2006. (Pubitemid 44036800)
24. Shi H, Huang Y, Zhou H, et al: Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 110: 2899-2906, 2007. (Pubitemid 350006943)
25. Faye C, Chautard E, Olsen BR and Ricard-Blum S: The first draft of the endostatin interaction network. J Biol Chem 284: 22041-22047, 2009.
26. Sethi G, Sung B and Aggarwal BB: Therapeutic Potential of VEGI/TL1A in Autoimmunity and Cancer. Adv Exp Med Biol 647: 207-215, 2009.